Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy

• DOI: 10.1038/s42003-021-01813-y
• Publication Date: 2021-02-24T11:03:35Z
• Authors: Abhinay Gontu; Sreenidhi Srinivasan; Eric Salazar; Meera Surendran Nair; Ruth H. Nissly; Denver Greenawalt; Ian M. Bird; Catherine M. Herzog; Matthew J. Ferrari; Indira Poojary; Robab Katani; Scott E. Lindner; Allen M. Minns; Randall Rossi; Paul A. Christensen; Brian Castillo; Jian Chen; Todd N. Eagar; Xin Yi; Picheng Zhao; Christopher Leveque; Randall J. Olsen; David W. Bernard; Jimmy Gollihar; Suresh V. Kuchipudi; James M. Musser; Vivek Kapur
• Keywords: Adult; Male; 0301 basic medicine; Time Factors; QH301-705.5; SARS-CoV-2; Age Factors; COVID-19; Blood Donors; Middle Aged; Antibodies, Viral; Antibodies, Neutralizing; Severity of Illness Index; Article; 3. Good health; Young Adult; 03 medical and health sciences; Immunoglobulin M; Immunoglobulin G; Humans; Female; Longitudinal Studies; Biology (General); Aged

AbstractMillions of individuals who have recovered from SARS-CoV-2 infection may be eligible to participate in convalescent plasma donor programs, yet the optimal window for donating high neutralizing titer convalescent plasma for COVID-19 immunotherapy remains unknown. Here we studied the response trajectories of antibodies directed to the SARS-CoV-2 surface spike glycoprotein and in vitro SARS-CoV-2 live virus neutralizing titers (VN) in 175 convalescent donors longitudinally sampled for up to 142 days post onset of symptoms (DPO). We observed robust IgM, IgG, and viral neutralization responses to SARS-CoV-2 that persist, in the aggregate, for at least 100 DPO. However, there is a notable decline in VN titers ≥160 for convalescent plasma therapy, starting 60 DPO. The results also show that individuals 30 years of age or younger have significantly lower VN, IgG and IgM antibody titers than those in the older age groups; and individuals with greater disease severity also have significantly higher IgM and IgG antibody titers. Taken together, these findings define the optimal window for donating convalescent plasma useful for immunotherapy of COVID-19 patients and reveal important predictors of an ideal plasma donor.